Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sarah Neill

Pulmonary Disease Owensboro, KY Medical Doctor

NPI 1518301514 CMS profile 5690054

1201 Pleasant Valley Rd, Ste 404, Owensboro, KY 42303

Open in the dashboard

General payments

$4,930

212 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sarah Neill of Owensboro, KY is reported in the CMS Open Payments database as having received $4,930 across 212 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 67th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $698 35
2024 General $906 50
2023 General $795 37
2022 General $1,140 55
2021 General $486 24
2020 General $350 4
2019 General $555 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sarah Neill
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Sarah Neill were reported at $698. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Sarah Neill Pulmonary Disease median Middle half National median
2019 $555 $377 $109–$1,340 $163
2020 $350 $230 $56–$907 $114
2021 $486 $269 $68–$1,072 $132
2022 $1,140 $390 $100–$1,457 $149
2023 $795 $419 $114–$1,659 $160
2024 $906 $476 $123–$1,818 $164
2025 $698 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $693 36 payments
  2. Actelion Pharmaceuticals US, Inc. $476 16 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $430 14 payments
  4. Insmed, Inc. $390 23 payments
  5. United Therapeutics Corporation $385 12 payments
  6. AstraZeneca Pharmaceuticals LP $280 14 payments
  7. Genzyme Corporation $213 10 payments
  8. Electromed, Inc. $207 9 payments
  9. Philips Electronics North America Corporation $179 9 payments
  10. Regeneron Healthcare Solutions, Inc. $175 10 payments
  11. Other $1,503 59 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,881 209 payments
  2. Education $49 3 payments
Products named General payments · program years 2019–2025
  1. UPTRAVI $440 14 payments
  2. Arikayce $390 23 payments
  3. NUCALA $367 21 payments
  4. OPSUMIT $320 10 payments
  5. TRELEGY ELLIPTA $219 14 payments
  6. DUPIXENT $213 10 payments
  7. ORENITRAM $207 2 payments
  8. FASENRA $201 9 payments
  9. TYVASO $200 7 payments
  10. Indigo System $161 2 payments
  11. Other $2,631 108 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 28 drugs

Part D claims

1,474

Median for Pulmonary Disease: 936

Drug cost

$722,324

Median for Pulmonary Disease: $487,987

Branded share of claims

76%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 63 $239,482
Ofev Nintedanib Esylate Brand 11 $145,601
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 93 $75,043
Spiriva Respimat Tiotropium Bromide Brand 125 $71,263
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 59 $44,024
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 85 $41,762
Breo Ellipta Fluticasone/Vilanterol Brand 49 $21,241
Symbicort Budesonide/Formoterol Fumarate Brand 50 $16,531
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 24 $13,457
Eliquis Apixaban Brand 15 $8,793

The 10 drugs with the highest cost, of 28 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 40 billing codes

Paid by Medicare

$117,521

Medicare's payments for the services billed

Medicare patients

378

Average age 74

Services billed

1,221

185 women, 193 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 57%
Arthritis 57%
COPD 54%
Heart failure 49%
Diabetes 44%
Chronic kidney disease 41%
Depression 41%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $100
  • Regeneron Healthcare Solutions, Inc. $33
$134 63 —
NUCALA
  • GlaxoSmithKline, LLC. $129
$129 — —
Arikayce
  • Insmed, Inc. $128
$128 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $108
$108 93 —
TYVASO
  • United Therapeutics Corporation $28
$28 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

212 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record